Download Files:
SNX-5422
SKU
HY-10213-10 mg
Category Reference compound
Tags Cancer, Cell Cycle/DNA Damage;Metabolic Enzyme/Protease, HSP
$95 – $750
Products Details
Product Description
– SNX-5422 (PF-04929113), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37 nM.
Web ID
– HY-10213
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C25H30F3N5O4
References
– [1]Huang KH, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009 Jul 23;52(14):4288-305|[2]Chandarlapaty S, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008 Jan 1;14(1):240-8.|[3]Kim SH, et al. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine. 2016 Feb;51(2):274-82.
CAS Number
– 908115-27-5
Molecular Weight
– 521.53
Compound Purity
– 96.52
SMILES
– FC(F)(C1=NN(C2=CC(N[C@@H]3CC[C@H](CC3)OC(CN)=O)=C(C=C2)C(N)=O)C(CC(C)(C4)C)=C1C4=O)F
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 32.5 mg/mL (ultrasonic)
Target
– HSP
Pathway
– Cell Cycle/DNA Damage;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.